NCT05887921 is a NA clinical trial of Inguinal Lymphadenectomy in Penile Cancer, sponsored by A.O.U. Città della Salute e della Scienza.

Who is sponsoring NCT05887921?

NCT05887921 is sponsored by A.O.U. Città della Salute e della Scienza.

What drugs are being tested in NCT05887921?

Interventions in NCT05887921: Inguinal Lymphadenectomy.

What condition does NCT05887921 study?

NCT05887921 studies Penile Cancer, Lymph Node Metastasis, Sentinel Lymph Node, Surgical Complication.

Is NCT05887921 still recruiting?

NCT05887921 is currently completed. Last updated 5 June 2023.

Last reviewed 2023-06-05 · How we verify

NCT05887921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inguinal Lymphadenectomy for Penile Cancer

Completed NA Last updated 5 June 2023

What this trial tests

NA trial testing Inguinal Lymphadenectomy in Penile Cancer in 14 participants. Completed in 24 May 2023.

Timeline

30 April 2019

Primary endpoint
22 December 2022

24 May 2023

Quick facts

Lead sponsor	A.O.U. Città della Salute e della Scienza
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	30 April 2019
Primary completion	22 December 2022
Estimated completion	24 May 2023
Sites	1 location across Italy

Drugs / interventions tested

Inguinal Lymphadenectomy

Conditions studied

Penile Cancer — all drugs for Penile Cancer →
Lymph Node Metastasis — all drugs for Lymph Node Metastasis →
Sentinel Lymph Node — all drugs for Sentinel Lymph Node →
Surgical Complication — all drugs for Surgical Complication →

Sponsor

A.O.U. Città della Salute e della Scienza — full company profile →

Who can join

Adults 18 to 80, male only, with Penile Cancer or Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study is to prospectively compare oncological and functional results of penile radical inguinal lymphadenectomy performed with an open versus videolaparoscopic technique. The main questions it aims to answer are: evaluated the oncological and functional results of inguinal lymphadenectomy performed with minimally invasive techniques using videolaparoscopic instruments vs open inguinal lymphadenectomy according to the standard technique. Participants will undergo treatment of the primary lesion and contextual inguinal lymphadenectomy: * Groin 1: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery * Groin 2: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery. The results of these procedures will be prospectively collected and compared.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inguinal Lymphadenectomy for Penile Cancer: An Interim Report from a Trial Comparing Open Versus Videoendoscopic Surgery Using a Within-patient Design.
Falcone M, Gül M, Peretti F, Preto M, et al · · 2024 · cited 5× · PMID 38558767 · DOI 10.1016/j.euros.2024.02.007

Verify or expand the search:

Other trials of Inguinal Lymphadenectomy

Trials testing the same drug.

NCT02166788 — Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma · Phase 3 · completed

Other recruiting trials for Penile Cancer

Currently open trials in the same condition.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07054307 — MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinom · Phase 1 · recruiting
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT06684327 — Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanc · Phase 2 · recruiting
NCT06683846 — Ivonescimab in the Treatment of Multiple Advanced Tumors · Phase 2 · recruiting

Other A.O.U. Città della Salute e della Scienza trials

Trials by the same sponsor.

NCT07535125 — IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN · not yet recruiting
NCT07017192 — OPPOSED (anteriOr hiP arthroPlasty regiOnal aneSthEsia stuDy) Study · NA · recruiting
NCT06690567 — Clinical Outcomes of Contemporary IMPELLA Devices in Cardiogenic Shock and High-risk Percutaneous Coronary Intervention · unknown
NCT06548438 — The Impact of PDD During TURB for NMIBC · Phase 4 · not yet recruiting
NCT07245524 — PeriOPerative Spine Surgery COntrol Pain (POPSSCOP) Study: Intrathecal Morphine vs Erector Spinae Plane Block for Postop · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05887921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by A.O.U. Città della Salute e della Scienza
Last refreshed: 5 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing